Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Sohei Hom"'
Autor:
Bertha Wojnarski, Chanthap Lon, Darapiseth Sea, Somethy Sok, Sabaithip Sriwichai, Soklyda Chann, Sohei Hom, Threechada Boonchan, Sokna Ly, Chandara Sok, Samon Nou, Pheaktra Oung, Nareth Kong, Vannak Pheap, Khengheang Thay, Vy Dao, Worachet Kuntawunginn, Mitra Feldman, Panita Gosi, Nillawan Buathong, Mali Ittiverakul, Nichapat Uthaimongkol, Rekol Huy, Michele Spring, Dysoley Lek, Philip Smith, Mark M Fukuda, Mariusz Wojnarski
Publikováno v:
PLoS ONE, Vol 15, Iss 1, p e0228207 (2020)
BACKGROUND:Primaquine is an approved radical cure treatment for Plasmodium vivax malaria but treatment can result in life-threatening hemolysis if given to a glucose-6-phosphate dehydrogenase deficient (G6PDd) patient. There is a need for reliable po
Externí odkaz:
https://doaj.org/article/ef08d2a9d03b4085b8f7f6c4f4c956af
Autor:
Pattaraporn Vanachayangkul, Darapiseth Sea, Mariusz Wojnarski, Somethy Sok, Chanikarn Kodchakorn, Winita Ta-aksorn, Sohei Hom, Mali Ittiverakul, Worachet Kuntawunginn, Montri Arsanok, Nillawan Buathong, Thay Kheang Heng, Kong Nareth, Samon Nou, Sok Chandara, Sokna Ly, Pheaktra Oung, Brian Vesely, Jason Bennett, Gregory Reichard, Brandon Pybus, Charlotte Lanteri, David Saunders, Mark Fukuda, Philip Smith, Lek Dysoley, Huy Rekol, Norman C. Waters, Michele Spring
Publikováno v:
Antimicrob Agents Chemother
The active metabolites of primaquine, in particular 5-hydroxyprimaquine, likely responsible for the clearance of dormant hypnozoites, are produced through the hepatic CYP450 2D6 (CYP2D6) enzymatic pathway. With the inherent instability of 5-hydroxypr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6c7c4fcc52d519f4e5c02be656dbde4
https://pubmed.ncbi.nlm.nih.gov/34978892
https://pubmed.ncbi.nlm.nih.gov/34978892
Autor:
Threechada Boonchan, Panita Gosi, Worachet Kuntawunginn, Soklyda Chann, Samon Nou, Rekol Huy, Dysoley Lek, Sabaithip Sriwichai, Nillawan Buathong, Darapiseth Sea, Vy Dao, Somethy Sok, Bertha Wojnarski, Nichapat Uthaimongkol, Mark M. Fukuda, Chanthap Lon, Pheaktra Oung, Michele D. Spring, Nareth Kong, Khengheang Thay, Sohei Hom, Sokna Ly, Mariusz Wojnarski, Mali Ittiverakul, Mitra Feldman, Philip A. Smith, Vannak Pheap, Chandara Sok
Publikováno v:
PLoS ONE
PLoS ONE, Vol 15, Iss 1, p e0228207 (2020)
PLoS ONE, Vol 15, Iss 1, p e0228207 (2020)
Background Primaquine is an approved radical cure treatment for Plasmodium vivax malaria but treatment can result in life-threatening hemolysis if given to a glucose-6-phosphate dehydrogenase deficient (G6PDd) patient. There is a need for reliable po
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b82c8c823ab924c57b43918dbfcc87e3
https://pubmed.ncbi.nlm.nih.gov/32004348
https://pubmed.ncbi.nlm.nih.gov/32004348